Owing to the large number of investigations requiring contrast media (CM), contrast-induced nephropathy (CIN) is one of the most common causes of acquired acute renal failure in the hospital environment (for recent review see Tepel et al. 1 ), thus causing considerable in-hospital morbidity and mortality. 2, 3 The definition of CIN varies. One definition 4,1 is a condition in which: During the usual course of CIN, serum creatinine returns to normal values within 1-3 weeks. The risk for developing CIN in patients with mild-to-moderate chronic renal insufficiency ranges between the studies from below 5% to more than 30%. 5 However, the likelihood for actually developing renal failure is considered to be much less (o1%). 6 Indeed, renal failure following CM administration is a rare event, 7 much lower than CIN. 8 The occurrence is so low that in most studies CIN is used as a surrogate marker for renal failure.
In this report, we seek to provide data on the occurrence of clinically significant renal failure for two different CM that were given during coronary procedures (coronary angiographies and percutaneous coronary interventions (PCI)). The present study includes over 57 000 patients from 23 hospitals in Sweden and does not rely on serum creatinine concentrations as a marker for the potential development of renal failure. Instead, the incidence of kidney damage is assessed by the re-hospitalization of these patients with a diagnosis of renal failure, or by required dialysis.
Patients at risk, for example, diabetic patients and patients with previous renal failure were also evaluated separately. This was carried out to avoid the influence of unequal distribution of these variables.
Moreover, in an additional analysis, we extended the observation period to include a third CM, iohexol that was commonly used in the 1990s. However, to avoid a time effect, the primary analysis was restricted to the years [2000] [2001] [2002] [2003] . During this time period, the percentage use of iodixanol and ioxaglate was stable.
The three investigated CM have different physicochemical properties (Table 1) . Iodixanol is an iso-osmolar compound, but has greater viscous properties. Iohexol has a considerably higher osmolality than plasma (but is referred to as a low-osmolar compound, as the osmolality is less than half as high as the pioneer CM). Ioxaglate is an ionic CM with similar osmolar and viscous properties as iohexol.
Aspelin et al. 9 showed in the NEPHRIC study that in 129 diabetic patients iso-osmolar iodixanol is much less likely to cause CIN than the low-osmolar agent iohexol. The NEPHRIC study used an increase in plasma creatinine to define CIN. In the accompanying editorial to the NEPHRIC study, Sandler 10 concluded that the results of NEPHRIC are encouraging, however, one should not yet conclude that iodixanol is the answer to contrast-agent-induced acute renal dysfunction and that we will have to depend on clinical studies to further elucidate this important problem. In contrast to NEPHRIC, the present study shows that iodixanol causes a higher incidence of clinically significant renal failure and dialysis than ioxaglate or iohexol.
RESULTS

Analysis 2000-2003 (groups 1-5)
Owing to the large group sizes, even minor differences in many known cofactors 11 can reach statistical significance (Table 2) . Figure 1 depicts the cumulative occurrence of clinically significant renal failure and dialysis. The values indicated on the y axis refer to the percentage of all patients that developed clinically significant renal failure at a certain time.
As can be seen, clinically significant renal failure after PCI or coronary angiography is uncommon (Table 3, Figure  1a -c), well below 1% of discharged patients during the first week had experienced clinically significant renal failure after the coronary procedure. This is different in patients that had previously been diagnosed with renal failure (Figure 1d ). In those patients that experienced renal failure before in life, reoccurrence of renal failure was observed in well over 30% of the patients.
Giving iodixanol instead of ioxaglate increased the occurrence of clinically significant renal failure markedly. This difference was seen both for the primary diagnosis of clinically significant renal failure (Table 3, Figure 1a ) and for the total (primary and secondary) diagnosis (Table 3 , Figure  1b ). Primary diagnosis of renal failure means that the main reason for the patient being treated was failure of the kidney. Secondary diagnosis means that other causes than renal failure were the predominant reason for treating the patient, but that renal failure was diagnosed during this treatment period. In accord with clinically significant renal failure, the need for subsequent dialysis following coronary procedures was significantly greater for the iodixanol-treated patients ( Figure 1c , Tables 2 and 3 ): For patients leaving a clinic within 1 month after PCI using ioxaglate, only 0.02% required dialysis. The value for the iodixanol-treated patients was fivefold higher (Po0.01). CM, contrast media. Data as provided by the compound specifications of the producers. In order to present values for an equivalent iodine concentration (320 mg/ml), the function curves were derived for various concentrations of CM. The interpolated values for 320 mg/ml were then taken. A center that switched CM is shown separately ( Figure  1e ). After changing CM to iodixanol, the risk to develop clinically significant renal failure within 3 months became significantly higher in the iodixanol (2.1%) compared to the ioxaglate patients (0.7%), Po0.001.
When only looking at the diabetic patients that are at higher risk for developing renal failure, the differences between the two CM groups remain. Ioxaglate caused less clinically significant renal failure in the high-risk group of diabetic patients (odds ratios: 0.59 vs 1, Po0.01, Table 4 ).
As for diabetics, patients that have previously experienced renal failure are also particularly vulnerable towards developing CIN. The separate analysis of this patient group revealed less renal failures in the ioxaglate-treated group (Figure 1d ), the odds ratio being 0.54 (vs 1 for iodixanol, Po0.01). The separate analyses of these high-risk patients underscore that an unbalance in covariates 'diabetes' (more often in the ioxaglate group) or 'previous renal failure' (more often in the iodixanol group) had no effect on the basic outcome. Intriguingly, the clinics that had shifted CM from to iodixanol experienced an increase in the occurrence of clinically significant renal failure (Figure 1e ). It is unlikely that the patient profiles, treatment of patients, and the criteria for diagnosing renal failure should have changed in these clinics from one year to the other. Rather it appears as if the type of CM causes the difference in the occurrence of clinically significant renal failure.
We also performed a multivariable regressive approach to properly compensate for differences in covariates (Tables 3  and 4 ). This is possible as the sample size is very large. Thus, the independent risk for clinically significant renal failure caused by the single risk factor was quantified and compensated for.
As an indication for the severity of the interventions, the proportion of stenting within the patient groups and the average amount of stents were analyzed. As seen in Table 2 , these values were similar between the groups. However, the slightly higher proportion of stenting in the ioxaglate group is significantly different. In total 86 334 patients were studied from 1990 to 2003. Iohexol used in 6,898 subjects. In 1990, iohexol was frequently used, whereas after 2000, there were no more clinics using this CM.
In later years, the indication for giving CM may have changed and patients at higher risk for CIN may have been given CM. Furthermore, hospitalization with a renal failure diagnosis in all is increasing with time. In Sweden, the numbers of hospitalizations with this diagnosis have increased by 26% between 1998 and 2003. 12 These restrictions must be kept in mind when interpreting the data for iohexol-treated patients in group 5. Treatment with this third CM caused a similar incidence of clinically significant renal failure within 3 months as ioxaglate (0.9 vs 0.8% for ioxaglate and 1.6% for iodixanol, Po0.001). Figure 1f is a long-term follow-up over 12 years. The marked increase of renal failure diagnosis following CM treatment is apparent during the first weeks. In the beginning, iodixanol leads to a much higher diagnosis rate of clinically significant renal failure. This difference (2% vs 1%) then remains stable over the next years. The constant slope after the immediate high-risk period indicates that the following risk to develop clinically significant renal failure is constant among the groups. In other words, iodixanol causes a greater risk for developing clinically significant renal failure during the first weeks after coronary interventions. After this period of high risk, the patients of all groups had the same risk for developing clinically significant renal failure (the slopes of the curves are very similar).
Hydration, plasma creatinine, and CM volumes All sites were contacted to determine specific hydration policies. These sites had hydration protocols and used these at least since 2000. Site-specific differences were detected with regard to fluids used (e.g., Ringer's solution or saline) and route of administration (p.o. or i.v.). However, we did not find any systematic differences between the ioxaglate using sites and the centers giving iodixanol. Thus, any differences seen are unlikely accounted for by various hydration regimens. A logistic regression model was used for compensations of differences in background and procedures (see Table 2 ). *n=number of patients included in the analysis where all cofactors are specified.
Doses of CM and plasma creatinine levels are documented in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) register since 2005. The data from these patients will be provided by the hospital discharge register by the second half of 2007.
During 2005 at the studied hospitals, 8100 patients have been recorded and do not indicate any significant differences in volume given (iodixanol: 138789 ml vs iogloxate: 1477105 ml; the median values were 110 and 120 ml, respectively). Moreover, the baseline creatinine values are comparable (iodixanol: 91754 mmol/l vs ioxaglate: 100756 mmol/l; median values: 83 mmol/l vs 92 mmol/l, respectively). Thus similar volumes of iodixanol and ioxaglate are given per intervention and the patients seem to have comparable renal function before the intervention.
DISCUSSION
The overall risk of developing clinically significant renal failure 3 months after giving CM for coronary interventions is between 1 and 2%. This is around one magnitude of order greater than an aged and gender-matched cohort of Sweden during the same years (0.131% p.a.). Patients receiving iodixanol had a higher risk of being re-hospitalized with a diagnosis of renal failure. The corresponding risk for patients receiving ioxaglate was significantly less (Figure 1 , Table 4 ). In accord, subsequent dialysis after coronary procedures occurred more often in the iodixanol-treated group. These differences were statistically significant as confirmed by multivariable analysis that compensates differences in the background characteristics.
Solomon et al. 13 have shown that even a minor increase in serum creatinine following CM use increases hospital stay on average by 4 days. Beyond the implications for public health, the choice of CM may have economical relevance. In districts of those hospitals using iodixanol, renal failure is diagnosed 16.7% more often than in the districts with hospitals using ioxaglate. 12 A large randomized prospective survey is required to fully elucidate the impact of various CM types on renal failure and the consequences for public health.
A third CM, iohexol, was commonly used in the beginning of the 1990s. Comparison of iohexol with the other two CM is difficult owing to substantial time effects. We therefore focus the analysis on the comparison between iodixanol and ioxaglate. However, it may still be appreciated that the risk to develop clinically significant renal failure seems to be significantly lower for the patients treated with this older CM than for those treated with the next generation of CM, iodixanol (Figure 1f) . It seems that the CM with lower viscosities have a reduced risk for developing clinically significant renal failure and dialysis.
The present findings seemingly contrast to two previous investigations. The first study, 14 suggested that iodixanol may be slightly less nephrotoxic than iohexol. In the second study, NEPHRIC, a considerable benefit for iodixanol vs iohexol was found for diabetic patients. 9 Comparing the presented findings with NEPHRIC and other studies is difficult, if not altogether impossible, as the end points and numbers are very different. Here we analyzed a very large database and used clinically significant renal failure and dialysis as end points. The NEPHRIC study involved diabetic patients only, as these are at higher risk for developing renal failure.
Therefore, as a subset, diabetic patients were analyzed separately in the present study (Table 4) . When only analyzing these diabetic patients, the outcome was as seen for the nondiabetic patients: iodixanol-treated patients experienced clinically significant renal failure twice as often as the patients of the ioxaglate group. Accordingly, the odds ratio was significantly higher for iodixanol (Table 4) . This subset analysis suggests that the higher incidence of clinically significant renal failure caused by iodixanol is independent from the distribution of diabetic patients among the groups.
The perception that iodixanol is of less damage to the kidney than other CM came about in 2003, when NEPHRIC was published. This is the last year of our analysis, but excluding this year does not affect the general outcome of the present study (data not shown).
Methodology and validation of the study
The shape of the Kaplan-Meier curves (Figure 1 ) may surprise. CIN is considered to be an acute phenomenon occurring during the first 3 days after CM is given. 4 After less than three weeks, plasma creatinine levels usually return to normal. In the present study, the diagnosis of renal failure was followed up for 3 months. Instead of only finding an immediate increase during the first days, the diagnosis renal failure leveled off rather late, that is, after 2 weeks-3 months. This has two obvious reasons: (1) A hospital discharge register was used. Thus, the final diagnosis was documented after the patient had been released from the clinic. This causes a considerable time delay. (2) Often there is a considerable delay until patients are reintroduced to the hospital. Taken together, these two factors cause a considerable lag, as seen in Figure 1 .
In Figure 1f , the follow-up for patients until 12 years is shown. As for the other panels of Figure 1 , the origin (i.e., time 0) refers to the application of CM. After the initial sharp increase in the diagnosis of renal failure during the first weeks, the risk for developing clinically significant renal failure is the same for all three groups (the three regressions run parallel). These linear slopes reflect the intrinsic risk for developing clinically significant renal failure. As the slopes do not differ among the groups of CM, there are no a priori differences in the intrinsic risk for developing clinically significant renal failure. The slopes of the curves indicate the risk for developing renal failure. Thus, the risk for renal failure remains constant for the years following the cardiac intervention.
Taken together, Figure 1f suggests that the CM given at the occasion of the coronary intervention causes an initial increase in the occurrence of clinically significant renal failure. Afterwards, when this challenge is over, the individual Kidney International groups once again take on the same risk for clinically significant renal failure.
It appears to be the CM itself that causes the higher risk of renal damage. This interpretation is underscored by the clinics that changed CM to iodixanol. Once iodixanol was in use, the risk for clinically significant renal failure and the need for dialysis dramatically increased (Figure 1e ). There is no indication that these clinics shifting to iodixanol changed the guidelines for diagnosing renal failure or that they suddenly recruited more patients at risk for renal failure. The CM itself causes this effect. However, it may be argued, that more patients at risk were treated in clinics using iodixanol. The contrary is true for diabetic patients (Table 2 ), but indeed the iodixanol-treated group contained larger numbers of renal failure. Therefore, another subset was formed including only these patients that had previously been diagnosed with renal failure (Table 4, Figure 1d ). This procedure eliminates the sample bias. When only looking at patients with previous renal failure, the odds ratio remains significantly lower for ioxaglate (0.54) than for iodixanol (1, Po0.01). Thus, again, the outcome of this study cannot be explained by more high-risk patients receiving iodixanol than ioxaglate. Taken together, many lines of evidence suggest that the baseline characteristics are comparable for the ioxaglate and iodixanol groups. Differences remain regarding the proportion of patients with previous renal failure. Logistic regression analyses and subset analyses of this high-risk group showed that this difference did not influence the outcome. If there were any undetected differences in group randomization, it is obvious that treatment with iodixanol was not successful in preventing CIN in these subjects.
Pathophysiological considerations
This study cannot clarify reasons for the differences in renal failure occurrence. Among the several discussed mechanisms involved in CIN (for review see Persson et al. 15 ), CM viscosity may deserve some consideration in understanding the higher incidence of renal failure in patients treated with iodixanol. Viscosity of the nonionic dimers is high which may be explained by various parameters, such as the so-called volumic fraction of the solute, that is, the volume of solvent occupied by hydrated molecules of the solute. This causes specific inter-molecular interactions (e.g., stacking) and, indirectly, influences shape and hydrophilicity.
Renal fluid uptake traps CM in the tubules, causing dramatic increases in fluid viscosity. 15 Iodixanol is very viscous (Table 1 ) and will not give rise to an osmotic diuresis as other hyperosmolar compounds. Thus, iodixanol becomes particularly concentrated upon renal tubular passage. Fluid viscosity is a known risk factor for renal damage, for example, it is one critical factor for the crush kidney, where excessive protein levels are observed and lead to kidney damage. Also, high viscous solutions such as molecular dextran have been shown to cause kidney damage. 16 However, many other factors such as cytotoxicity and apoptosis must be considered as further possible mediators.
Conclusion
In this study, we find no indication that use of the isoosmolar CM iodixanol results in less damage to the kidney than use of the higher osmolar CM ioxaglate. In fact, the contrary seems to be the case.
MATERIALS AND METHODS Patients
This study was carried out of data from Swedish hospitals that only use one specific contrast medium compound. The SCAAR documents patients from all centers performing PCI and/or coronary angiography in Sweden. By 31 December 2003, information from 181 446 coronary procedures (81 677 PCIs and the rest only diagnostic catheterizations) in 127 098 patients had been collected in SCAAR. The patients were classified according to the CM given. Parameters such as age, gender, indication of the procedure, the extent of the coronary disease, and complications were recorded in the register. For the PCI-treated patients, also information about coronary risk factors, for example, diabetes, previous coronary interventions, and procedural data were collected. Information regarding hydration strategy was not recorded in the SCAAR, the type and amount of CM as well as baseline plasma creatinine has been added in 2005.
The following groups were studied: In Sweden, hospitals performing coronary procedures only use one specific CM. Three hospitals switched over from iohexol to iodixanol (between 1995 and 1997), and one hospital from ioxaglate to iodixanol in 2000. Three hospitals switched over from iohexol to iodixanol (between 1995 and 1997), and one hospital from ioxaglate to iodixanol in 2000. During the transition year no patients from these hospitals were included in the analysis to avoid incorrect grouping.
The diagnosis of renal failure was taken from the 'Hospital Discharge Register', a national register run by the Swedish government. 17, 18 By combining the SCAAR and the Swedish allnational 'Hospital Discharge Register' hospitalizations with diagnosis of renal failure (main and secondary) and of required dialysis of the patients could be followed up to the 31 December 2003. The definition of renal insufficiency was according to ICD-9 (585 or 586) and ICD-10 (N14, N17-19, or N99) and of dialysis ICD-9 (V56A or V45B) and ICD-10 (Z49 or Z99.2) or procedure code v9211, v9212, v9200, v9531, or v9532. Diabetes was defined as recorded in SCAAR. If the information was missing in SCAAR, the patients were defined as having diabetes if there was any previous hospitalization with a diagnosis of diabetes mellitus.
Patients with documented previous dialysis were excluded in the analysis of subsequent dialysis after the coronary procedures.
The combination of the two registers was carried out in cooperation with the Swedish National Board of Health and Welfare and was approved by the local ethics committee at the University of Uppsala.
The study complied with the Declaration of Helsinki Principles.
Data analyses
Two hospitals, one with an iodixanol policy, the other using ioxaglate were examined to verify the exclusiveness of the CM given. In total, 9305 patients from our study were treated in these centers. In all cases the predicted CM had been given. One-way analysis of variance was used for continuous variables and the Pearson w 2 test for categorical data. Kaplan-Meier curves depict hospitalizations with a diagnosis of renal insufficiency within 3 months from the last coronary procedure. The time axis refers to the date when these patients left the hospital, that is, at the time where the diagnosis was documented after having been treated.
Multivariable Logistic regression analyses were performed to evaluate the effect of CM strategy on the renal insufficiency after the coronary procedures. In our model, we entered relevant clinical background variables as specified in Table 2 . Multivariable analyses, also compensated for differences in these covariates.
Po0.05 was considered statistically significant. Data processing and statistical analyses were performed by SPSS 11.5.1.
